[1] Colonna M, Brooks EG, Ferrara GB, et al. Generation of allospecific natural killer cells by stimuluLation across a polymorphism of HLA-C. Science. 1993;260(5111):1121- 1124.
[2] Li J, Qu X, Zhang C, et al. Characterization of 236 novel alleles at the HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 loci from China Marrow Donor Program. Tissue Antigens. 2011; 78:267-270.
[3] 高素青,徐筠娉,王大明,等. HLA-Cw基因常规检测区外第1、5、6、7外显子核苷酸序列测定的研究及临床应用[J].中华检验医学杂志,2011,33(6):513-516.
[4] Petemdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997;89:1818-1823.
[5] Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated donors:the impact of mismatches with substitutions at position 116 of the human|eukocyte antigen class I heavy chain. Blood. 2001; 98:3150-3155.
[6] Chalandon Y, Tiercy JM, Schanz U, et al. Impact of high resolution matching in allogeneie unrelated donor stem cell transplantation in Switzerland. Bone Marrow Transplant. 2006;37:909-916.
[7] Loiseau P, Busson M, Balere ML, et al. HLA Association with hematopoielie stem cell transplantation outcome:the number of mismatches at HLA-A, -B, -C, -DRBI, or -DQBI is strongly associated with overall survival. Biol Blood Marrow Transplant. 2007;13:965-974.
[8] 王大明,邹红岩,何柳媚,等.一例供者携带的C* 03:100等位基因的测序分析[J].国际输血及血液学杂志,2012,35(5):390-392.
[9] Cano P, Klitz W, Mack SJ, et al. Common and well-documented HLA alleles: report of the Ad-Hoc committee of the american society for histocompatiblity and immunogenetics. Hum Immunol. 2007;68:392-417.
[10] Kobayashi S, Kikuta A, Ito M, et al. Loss of mismatched HLA in myeloid/NK cell precursor acute leukemia relapse after T cell-replete haploidentical hematopoietic stem cell transplantation. Pediatric Blood Cancer. 2014;61(10): 1880-1882.
[11] 王大明,何柳媚,邹红岩,等. 4例人类白细胞抗原罕见等位基因的结果分析[J].中国组织工程研究,2013,17(44):7809-7814.
[12] Wang DM, Xu YP, Deng ZH. Identification of a novel HLA-C*01 variant allele, C*01:46. Tissue Antigens. 2011;78: 70-71.
[13] Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119(17):3908-3916.
[14] Spellman S, Klein J, Haagenson M, et al. Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(5):739-746.
[15] Askar M, Sobecks R, Morishima Y, et al. Predictions in the face of clinical reality:HistoCheck versus high-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(9):1409-1415.
[16] Petersdorf EW, Malkki M, Horowitz MM, et al. Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. Blood. 2013;121(10):1896-1905.
[17] ratwohl A, Brand R, Niederwieser D, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29(15):1980-1986.
[18] Lee SJ, Klein J, Haagenson M, et al. High-resolution donor- recipient HLAmatching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-83.
[19] Arora M, Weisdorf D, Stephen R. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009;27:1644-1652.
[20] Shikari H, Amparo F, Saboo U, et al. Onset of ocular graft- versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation. Cornea. 2015; 34(3):243-247.
[21] Zheng CC, Zhu XY, Tang BL, et al. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia. Ann Hematol. 2015; 94(3):473-480.
[22] Remberger M, Beelen DW, Fauser A, et al. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood. 2005;105:548-551.
[23] 23. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;11(99):4200-4206.
[24] Greinix HT, Fae I, Schneider B, et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant. 2005;35:57-62.
[25] Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: Comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971-1977.
[26] Mohamed M. Immunology of hematopoietic stem cell transplantation. Immunol Invest. 2014;43(8):1-30
[27] Hladun R, Badell I, González M, et al. Survival analysis of hematopoietic stem cell transplantation in children with primary immunodeficiency in Spain. An Pediatr (Barc). 2014;82(2):62-67.
[28] Alois G, Helen B, Jakob P. Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol. 2013;20(6):485-493.
[29] Marcelo A. Fernandez V, Wang T, et al. Identication of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood. 2014;123(8):1270-1278.
[30] Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923-1930.
[31] Brunstein CG. Wanted: prospective studies of alternative donors. Biol Blood Marrow Transplant. 2015;21(6):957-958.
[32] Perusco A, Gamba C, Galarza P, et al. HLA antigenic and haplotype frequencies estimated in hematopoietic progenitor cell donors from Argentina. Transplant Proc. 2014;46(9):3064-3067.
[33] Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339-348.
[34] Grubic Z, Burek Kamenaric M, et al. HLA-A, HLA-B and HLA-DRB1 allele and haplotype diversity among volunteer bone marrow donors from Croatia. Int J Immunogenet. 2014;41(3):211-221.
[35] Testi M, Andreani M, Locatelli F, et al. Influence of the HLA characteristics of Italian patients on donor search outcome in unrelated hematopoietic stem cell transplantation. Tissue Antigens. 2014;84(2):198-205.
[36] Gourraud PA, Balère ML, Faucher C, et al. HLA phenotypes of candidates for HSCT: comparing transplanted versus non-transplanted candidates, resulting in the predictive estimation of the probability to find a 10/10 HLA matched donor. Tissue Antigens. 2014;83(1):17-26.
[37] Bemer MJ, Sorror M, Sandmaier BM, et al. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer Chemother Pharmacol. 2013;72(3):607-618.
[38] Bäuerlein CA, Riedel SS, Baker J, et al. A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model. BMC Med. 2013; 11:134.
[39] Hombrink P, Hassan C, Kester MG, et al. Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach. J Immunol. 2013;190(8):3869-3877.
[40] Grubic Z, Stingl K, Zunec R. Heterogeneity of HLA-DRB1*04 alleles and haplotypes in the Croatian population. Tissue Antigens. 2012;80(3):219-223.
[41] Thiel U, Wolf P, Wawer A, et al. Human leukocyte antigen distribution in German Caucasians with advanced Ewing's sarcoma. Klin Padiatr. 2012;224(6):353-358.
[42] Kuwatsuka Y, Kohno A, Terakura S, et al. Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. Cancer Sci. 2012;103(9):1688-1694.
[43] Mori T, Kato J, Shimizu T, et al. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Biol Blood Marrow Transplant. 2012; 18(2):229-234.
[44] Sobecks RM, Askar M, Thomas D, et al. Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype. Exp Clin Transplant. 2011;9(1):7-13.
[45] Viswanathan C, Roy A, Damodaran D, et al. Optimization of the inventory size of the public cord blood program-the Indian context. J Assoc Physicians India. 2010;58:608-611.
[46] Rosenmayr A, Pointner-Prager M, Mitterschiffthaler A, et al. What are a patient's current chances of finding a matched unrelated donor? Twenty years' central search experience in a small country. Bone Marrow Transplant. 2012;47(2): 172-180.
[47] Kanda J, Lopez RD, Rizzieri DA. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93(5):586-593.
[48] Testi M, Lai S, Orrù S, et al. Distribution of HLA alleles and haplotypes in the Maldivian population. Tissue Antigens. 2011;77(3):235-238.
[49] Balas A, García-Sánchez F, Vicario JL. Allelic and haplotypic HLA frequency distribution in Spanish hematopoietic patients. Implications for unrelated donor searching. Tissue Antigens. 2011;77(1):45-53.
[50] Willemze R, Ruggeri A, Purtill D, et al. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation? Best Pract Res Clin Haematol. 2010; 23(2):283-290.
|